• Follow us on Twitter

Follow us on Twitter:

The RTCure project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement no 777357. This joint undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and EFPIA.

The communication reflects the author's view; neither IMI nor the European Union or EFPIA  are responsible for any use that may be made of the information contained herein.

Objectives

The specific objectives of WP5 are:

  1. Provide solutions to store, curate, access, analyse and visualize large and highly dimensional datasets generated as part of the RTCure consortium. Data types described by WP participants that already exist or will be generated include but are not limited to: patient reported, clinical, genetic, epigenetic, transcriptomic, proteomic, microbiome, metabolomics, and immunophenotype

  2. Collaborate with WPs 2, 3 and 4 to determine which of their data are in scope for WP5 and define an optimal data management and analysis plan to facilitate achievement of their analytical goals.

  3. Utilize the developed insight, systems, and results from the above analyses to collaborate with WP6 on clinical trials with regard to

    • Analysis of selected datasets

    • Selection of biomarker assays

    • Patient segmentation

    • Treatment strategies

Partners

  • KI

  • DRFZ

  • MUW

  • UKER

  • LUMC (lead)

  • UQ

  • ANOCCA

  • Janssen

  • UCB

  • GSK

  • Sanofi

  • BMS

  • PFIZER (lead)

WP5 - Bioinformatics and data